Advertisement

Topics

Latest Gastroenterology NewsRSS

16:03 EDT 26th September 2017 | BioPortfolio

Investigators at Children’s Hospital Los Angeles Identify Pathway that Causes Immune Cells to Support Cancer, Instead of Killing It

Investigators at the Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles have identified new findings about an immune cell – called a tumor-associated macrophage – that promotes cancer instead of fighting it. They have identified the molecular pathway, known as STAT3, as the mechanism the immune cell uses to foster ne...

Alzheimer disease new drugs, markets and companies [Report Updated: 08092017] Prices from USD $4000

SummaryAlzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic...

Dr. David Samadi Provides Free Consultations for Men Newly Diagnosed with Prostate Cancer

NEW YORK, Sept. 26, 2017 /PRNewswire/ -- In support of Prostate Cancer Awareness month, Dr. David Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital in New York City, will offer free consultation to men newly diagnosed with prostate cancer. It is Dr. Samadi's mission to bring awareness to the early stages of this potentially deadly disease affecting about 1 in 7 m...

Newly Published Data Supports Avelas Biosciences' Investigational Ratiometric Activatable Fluorescent Peptide AVB-620 in Intraoperative Tumor Detection

SAN DIEGO, Sept. 26, 2017 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced publication of data from its Phase 1b clinical study evaluating the company's lead candidate, AVB-620, in Annals of Surgical Oncology, the official journal of the Society of Surgical Oncology and t...

Golf Outing: Ice Mobility Announces 2nd Annual Charity Golf Outing Benefiting the Leukemia and Lymphoma Society

LINCOLNSHIRE, Ill., Sept. 26, 2017 /PRNewswire/ -- Ice Mobility announced today that its 2nd Annual Charity Golf Outing, a fundraising golf event, will take place on October 4, 2017 at White Deer Run Golf Course in Vernon Hills, Illinois.  All proceeds from the event will benefit the Leukemia and Lymphoma Society.  White Deer Run is a premier North Shore golf course built on the fam...

Reflow Medical Announces 510(k) Clearance to Market Wingman Crossing Catheter for Coronary Indication

Reflow Medical, Inc., a developer and innovator of crossing and support catheters for use in the treatment of occlusive cardiovascular disease, announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Wingman14C Crossing Catheter for use in conjunction with a guidewire to access discrete ...

Montclair State Public Relations Student Society of America Set to Host Zombie Walk to Raise Money for the John Theurer Cancer Center at Hackensack University Medical Center

MONTCLAIR, N.J., Sept. 26, 2017 /PRNewswire/ -- On Sunday, October 22, zombies will gather at Dioguardi Field at Montclair State University for the university's inaugural "2K Walking Dead for Life" run to raise money for the John Theurer Cancer Center at Hackensack University Medical Center.  The event is also a zombie costume competition, which will be judged by Tony Award winning costu...

Study Identifies Likely Scenarios for Global Spread of Devastating Crop Disease

A team of scientists from the University of Cambridge, the United Kingdom Met Office and the International Maize and Wheat Improvement Centre (CIMMYT) has used adapted modeling systems to predict when and how wheat stem rust is most likely to spread around the world. Wheat rust, especially aggressive new strains such as “Ug99,” first detected in Uganda in 1999, causes global economic losses of...

Breast Cancer Patients Offered Free Dental Screening after Study Links Gum Disease to Breast Cancer Risk

A new study linking gum disease to a 14% increased risk for breast cancer inspires a Seattle-area dentist to offer breast cancer patients a free high-tech dental screening and evaluation in recognition of National Breast Cancer Awareness Month and National Dental Hygiene Month in October. Bellevue, WA (PRWEB) September 26, 2017 Women with gum disease are 14% more likely to develop cancer accordin...

The VCA Pet Cancer Alliance at VCA Animal Diagnostic Clinic is on Forefront of Pet Cancer Treatment

State-of-the-art technologies and multi-disciplinary approach provides effective treatment In a promising development for pet cancer patients, VCA’s Pet Cancer Alliance at Animal Diagnostic Clinic (ADC) now provides specialized cancer treatment for pets in a caring and healing environment. ADC’s team of board certified specialists uses a multi-disc...

Inhibitors to Vampire Kissing Bug Parasite Discovered

Parasitic infections have been notoriously difficult to treat and as such have become a public health threat in many parts of the world. One such infection, called Chagas disease, was originally confined to parts of Latin and South Americas; however, worldwide travel has spread the disease, which is now endemic to approximately 20 countries and beginning to encroach onto the borders of the U.S. Th...

France Tumor Marker Testing Analyzers and Reagents Market 2021: Supplier Shares and Sales ForecastsCompetitive Intelligence, Technology and Instrumentation Review, Opportunities for Suppliers [Report Updated: 25082017] Prices from USD $6800

HighlightsComprehensive 585page analysis of the French tumor marker testing market.Major issues pertaining to the French laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, pr...

DFB Soria Gives Update on Enrollment in Phase 2 Clinical Trial of SOR007 (Nanoparticle Paclitaxel) Ointment for Actinic Keratosis (AK)

AK can lead to the second most common form of skin cancer DFB Soria, a clinical-stage pharmaceutical development company, and an affiliate of NanOlogy™, today announced completion of the second of four

Glythera licenses novel payload class from Cancer Research UK for the development of next-generation antibody drug conjugates.

Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor programme for the development of ADCs conjugated using its highly stable conjugation platform, PermaLink® Glythera will generate multiple ADCs with improved therapeutic index directed towards antigens specific to difficult-to-treat tumours, combining CDK11 inhibitors with its growing in-house antibo...

Hyundai Hope On Wheels Awards $250,000 Research Grant To Mayo Clinic's Children's Research Center In Honor Of National Childhood Cancer Awareness Month

ROCHESTER, Minn., Sept. 26, 2017 /PRNewswire/ -- Hyundai Hope On Wheels® will today present Mayo Clinic's Children's Research Center with a $250,000 Hyundai Scholar Hope Grant. The grant funds will support the research of principal investigator Dr. Paul Galardy. This award is part of the organization's efforts during National Childhood Cancer Awareness Month.  In September alone, Hope O...

Guardant Health Receives Investigational Device Exemption Approval from the FDA to Support Merck KGaA, Darmstadt, Germany Tepotinib Study

REDWOOD CITY, Calif., Sept. 26, 2017 /PRNewswire/ -- Guardant Health announced that it received an investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to provide genomic testing for a clinical trial investigating the small molecule, c-Met kinase inhibitor tepotinib. Under a collaboration agreement between Guardant Health and Merck KGaA, Darmstadt, ...

Glythera Licenses Novel Payload Class from Cancer Research UK for the Development of Next-Generation Antibody Drug Conjugates

Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor programme for the development of ADCs conjugated using its highly stable conjugation platform, PermaLink® Glythera will generate multiple ADCs with improved therapeutic index directed towards antigens specific to difficult-to-treat tumours, comb...

SYNERGYS Announces Phase 1 SBIR Grant Award From National Institutes of Health

Grant will support development of Vasculogenic Mimicry-blocking Antibody Fusion products for Triple Negative Breast Cancer Synergys Biotherapeutics, a preclinical stage biotherapeutics company developing Vasculogenic Mimicry (VM)-blocking antibody drugs announced today the receipt of a Phase I grant from the National Cancer Institute under auspi...

Protein Linking Key Organelles May Shed Light on Neurodegenerative Disease Development

Scientists report that they have developed a technique to identify proteins that allow the mitochondria and the endoplasmic reticulum to attach to each other. Faulty connections between the ER and mitochondria have been implicated in several neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's disease. The research ("Ascorbate peroxidase pr...

Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models

HACKENSACK, N.J., Sept. 26, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the signing of a competitive contract through the government's Small Business Innovation Research (SBIR) program. The contract is in respon...

Goldfinch Bio Expands Leadership Team with World-Class Preclinical and Clinical Expertise to Augment Company's Unprecedented Investigation into the Molecular Drivers of Kidney Disease

CAMBRIDGE, Mass., Sept. 26, 2017 /PRNewswire/ -- Goldfinch Bio, a company singularly focused on discovering and developing precision therapies to treat patients with kidney disease, today announced that it has expanded its leadership team with the addition of Maria Beconi, Ph.D. as vice president of pharmacology and non-clinical development, and Liron Walsh, M.D. as vice president of translat...

Put an End to "Sclero-What" During June's Scleroderma Awareness Month

DANVERS, Mass., May 29, 2014 /PRNewswire-USNewswire/ -- Too many people in the United States know nothing about scleroderma, a mysterious and frequently disabling condition, which affects an estimated 300,000 people, so this June the Scleroderma Foundation wants to increase awareness of the disease that can strip away a person's independence and quality of life. Scleroderma strikes women 4-to-1 ov...

10-year Data Shows CyberKnife® System Provides Excellent Long-term Control of Low-Risk Prostate Cancer

SUNNYVALE, Calif., Sept. 26, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent had local disease control 10 years after receiving stereotactic body radiation therapy (SBRT) administered with the CyberKnife® System, and toxicity was mild. The study titled, "Stereotactic Body Radio...

Roivant Sciences Statement on MINDSET Results

BASEL, Switzerland, Sept. 26, 2017 /PRNewswire/ -- Today our subsidiary Axovant announced topline results from its Phase 3 MINDSET trial of intepirdine in mild-to-moderate Alzheimer's disease. Unfortunately, intepirdine did not achieve a statistically significant result on the primary endpoints of the study. Patients and physicians have witnessed an unrelenting series of failures in Alzheimer'...

BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration

TEL AVIV, Israel, September 26, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of a Phase 1b/2 trial for BL-8040 in combination with atezolizumab (TECENTRIQ®), an anti-PDL1 cancer immunotherapy from Genentech, a member of the Roche Group. The trial, known as the BATT...

Quick Search
Advertisement
 

review and buy Gastroenterology market research data and corporate reports here